Skip to main content

Advertisement

SpringerLink
Log in

A novel immunogenomic classification for prognosis in non-small cell lung cancer

  • Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Objective

To facilitate immunotherapy and prognostic assessment of non-small cell lung cancer (NSCLC), we established a novel immunogenomic classification to provide valid identification criteria.

Methods

The immune enrichment scores were calculated by single sample gene set enrichment analysis (ssGSEA) and clustered into Immunity_L and Immunity_H, and the reliability of this classification was demonstrated. Immune microenvironment score and immune cell infiltration analysis of NSCLC were also performed. Randomly divided into training group and test group, a prognosis-related immune profile was developed using least absolute shrinkage and selection operator (LASSO) and stepwise COX proportional hazards model to construct a prognostic mode.

Results

The risk score for this immune profile was identified as an independent prognostic factor and can be used as a powerful prognostic tool to refine tumor immunotherapy. Our study identified two NSCLC classifications based on immunomic profiling, Immunity_H and Immunity_L.

Conclusion

In conclusion, Immunogenomic classification can distinguish the immune status of different types of NSCLC patients and contribute to the immunotherapy of NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Data availability

All data can be retrieved from TCGA database (https://portal.gdc.cancer.gov) and ImmPort database (https://www.immport.org/).

References

  • Al-Shibli KI, Donnem T, Al-Saad S et al (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 14(16):5220–5227

    Article  CAS  PubMed  Google Scholar 

  • Angénieux C, Fraisier V, Maître B et al (2005) The cellular pathway of CD1e in immature and maturing dendritic cells. Traffic (copenhagen, Denmark) 6(4):286–302

    Article  PubMed  Google Scholar 

  • Aran D, Lasry A, Zinger A et al (2016) Widespread parainflammation in human cancer. Genome Biol 17(1):145

    Article  PubMed  PubMed Central  Google Scholar 

  • Bremnes RM, Al-Shibli K, Donnem T et al (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 6(4):824–833

    Article  PubMed  Google Scholar 

  • Camidge DR, Doebele RC, Kerr KM (2019) Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol 16(6):341–355

    Article  CAS  PubMed  Google Scholar 

  • Chen T, Li J, Zhou MH et al (2020) IL-6 stimulates lncRNA ZEB2-AS1 to aggravate the progression of non-small cell lung cancer through activating STAT1. Eur Rev Med Pharmacol Sci 24(7):3734–3740

    CAS  PubMed  Google Scholar 

  • Datar IJ, Hauc SC, Desai S et al (2021) Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 27(10):2837–2847

    Article  CAS  PubMed  Google Scholar 

  • Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998

    Article  CAS  PubMed  Google Scholar 

  • Ghorani E, Rosenthal R, Mcgranahan N et al (2018) Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Annals of Oncology : Official Journal of the European Society for Medical Oncology 29(1):271–279

    Article  CAS  PubMed  Google Scholar 

  • Hackshaw AK, Law MR, Wald NJ (1997) The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ (clin Res Ed) 315(7114):980–988

    Article  CAS  Google Scholar 

  • Herbst RS, Baas P, Kim D-W et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (london, England) 387(10027):1540–1550

    Article  CAS  PubMed  Google Scholar 

  • Huang J-X, Wu Y-C, Cheng Y-Y et al (2019) IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells. Onco Targets Ther 12:11475–11486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keating GM (2016) Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. Drugs 76(9):969–978

    Article  CAS  PubMed  Google Scholar 

  • Korman AJ, Garrett-Thomson SC, Lonberg N (2022) The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discovery 21(7):509–528

    Article  CAS  PubMed  Google Scholar 

  • Lambert SA, Jolma A, Campitelli LF et al (2018) The Human Transcription Factors. Cell 172(4):650–665

    Article  CAS  PubMed  Google Scholar 

  • Lin A, Zhu CC, Chen HX et al (2010) Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer. J Cell Mol Med 14(9):2318–2329

    Article  CAS  PubMed  Google Scholar 

  • Liu C, Li X, Hao Y et al (2020) STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis. Aging 12(9):8680–8701

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lu J, Zhong R, Lou Y et al (2021) Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. Front Immunol 12:732125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594

    Article  PubMed  Google Scholar 

  • Mollaoglu G, Jones A, Wait S J, et al. The Lineage-Defining Transcription Factors SOX2 and NKX2–1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity, 2018, 49(4).

  • Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27(28):3889–3900

    Article  CAS  PubMed  Google Scholar 

  • Pribluda A, Elyada E, Wiener Z et al (2013) A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24(2):242–256

    Article  CAS  PubMed  Google Scholar 

  • Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Research, 2012, 40(Database issue): D71-D75.

  • Ritchie ME, Phipson B, Wu D et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47

    Article  PubMed  PubMed Central  Google Scholar 

  • Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (london, England) 389(10066):255–265

    Article  PubMed  Google Scholar 

  • Rock KL, Reits E, Neefjes J (2016) Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol 37(11):724–737

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schütt P, Schütt B, Switala M et al (2010) Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 71(5):489–495

    Article  PubMed  Google Scholar 

  • Shao W, Yang Z, Fu Y et al (2021) The Pyroptosis-Related Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Gastric Cancer. Frontiers in Cell and Developmental Biology 9:676485

    Article  PubMed  PubMed Central  Google Scholar 

  • Shibru B, Fey K, Fricke S et al (2021) Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry. Front Immunol 12:694055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shimizu K, Okita R, Saisho S et al (2017) Urinary levels of prostaglandin E are positively correlated with intratumoral infiltration of Foxp3 regulatory T cells in non-small cell lung cancer. Oncol Lett 14(2):1615–1620

    Article  PubMed  PubMed Central  Google Scholar 

  • Su C, Wang X, Zhou J et al (2021) Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. Translational Lung Cancer Research 10(3):1256–1265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vaquerizas JM, Kummerfeld SK, Teichmann SA et al (2009) A census of human transcription factors: function, expression and evolution. Nat Rev Genet 10(4):252–263

    Article  CAS  PubMed  Google Scholar 

  • Vineis P, Airoldi L, Veglia F et al (2005) Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ (clin Res Ed) 330(7486):277

    Article  CAS  Google Scholar 

  • Wakabayashi O, Yamazaki K, Oizumi S et al (2003) CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94(11):1003–1009

    Article  CAS  PubMed  Google Scholar 

  • Wang M, Herbst RS, Boshoff C (2021) Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 27(8):1345–1356

    Article  CAS  PubMed  Google Scholar 

  • William D. Travis E B, Allen Burke, Alexander Marx, Andrew G. Nicholson. WHO ****Classification of Tumours of the Lung, Pleura, Thymus and Heart[M]. Lyon: International Agency for Research on Cancer, 2015.

  • Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6(10):715–727

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

All authors would like to thank the research groups for TCGA and providers of other databases mentioned in the paper.

Funding

This work was supported by the National Nature Science Foundation of China (No. 81703759).

Author information

Author notes

  1. Shu Tang and Liqing Xu contributed equally to this work.

Authors and Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, No. 1, East Construction Road, Zhengzhou, 450052, China

    Shu Tang, Liqing Xu, Zhanshen Wu, Hui Li & Na Li

  2. Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, 450052, China

    Qiang Wen

Authors
  1. Shu Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liqing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhanshen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiang Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Na Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XLQ and WZS was responsible for downloading and processing the data in this paper and writing the paper. LH was responsible for reviewing the data in this paper and drawing the graphs and tables. TS was responsible for the design of this study and reviewing the full text; WQ and LN were responsible for reviewing the full text. All authors read and approved the final version.

Corresponding author

Correspondence to Shu Tang.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, S., Xu, L., Wu, Z. et al. A novel immunogenomic classification for prognosis in non-small cell lung cancer. J Cancer Res Clin Oncol 149, 10951–10964 (2023). https://doi.org/10.1007/s00432-023-04887-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-04887-9

Keywords

Search

Navigation